Search This Blog

Thursday, August 6, 2026

OraSure delaying InteliQuick CT/NG FDA clearance beyond 2026

 

OraSure Technologies posts Q2 2026 non-GAAP EPS $0.09 and revenue $30.6M, beating EPS and revenue estimates

  • Non-GAAP EPS of $0.09 increased 135% year-over-year in fiscal Q2 2026.
  • Q2 2026 revenue of $30.6M declined 2% year-over-year from the prior-year period.
  • Revenue of $30.6 million beat OraSure's Q2 2026 revenue guidance.
  • OraSure reported Q2 2026 GAAP net income of $6.2 million.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)